Through the 90-day period concluding February 19, 2026, Intensity Therapeutics's top three insider stakeholders include Principal Accounting Officer John M Wesolowski (85.35K shares), Chief Financial Officer Joseph Talamo (28.66K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| John M Wesolowski | Principal Accounting Officer | 85,354 | 05 Jan, 2026 |
| Joseph Talamo | Chief Financial Officer | 28,661 | 05 Jan, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 31 Dec, 2025 | Joseph Talamo | Common Stock, $0.0001 Par Value | A | 14,482 | $0.26 | 28,661 | D | A |
| 31 Dec, 2025 | John M Wesolowski | Common Stock, $0.0001 Par Value | A | 8,918 | $0.26 | 85,354 | D | A |
| 30 Jun, 2025 | Joseph Talamo | Common Stock, $0.0001 Par Value | A | 14,179 | $0.26 | 14,179 | D | A |
| 30 Jun, 2025 | John M Wesolowski | Common Stock, $0.0001 Par Value | A | 69,745 | $0.26 | 76,436 | D | A |
| 05 Jun, 2024 | John M Wesolowski | Common Stock, $0.0001 Par Value | A | 1,000 | $4.00 | 6,691 | D | M |